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Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder with a polygenic mode of inheritance. This study examined the
hypothesis that runs of homozygosity (ROHs) play a recessive-acting role in the underlying RA genetic mechanism and
identified RA-associated ROHs. Ours is the first genome-wide homozygosity association study for RA and characterized the
ROH patterns associated with RA in the genomes of 2,000 RA patients and 3,000 normal controls of the Wellcome Trust Case
Control Consortium. Genome scans consistently pinpointed two regions within the human major histocompatibility
complex region containing RA-associated ROHs. The first region is from 32,451,664 bp to 32,846,093 bp
(2log10(p).22.6591). RA-susceptibility genes, such as HLA-DRB1, are contained in this region. The second region ranges
from 32,933,485 bp to 33,585,118 bp (2log10(p).8.3644) and contains other HLA-DPA1 and HLA-DPB1 genes. These two
regions are physically close but are located in different blocks of linkage disequilibrium, and ,40% of the RA patients’
genomes carry these ROHs in the two regions. By analyzing homozygote intensities, an ROH that is anchored by the single
nucleotide polymorphism rs2027852 and flanked by HLA-DRB6 and HLA-DRB1 was found associated with increased risk for
RA. The presence of this risky ROH provides a 62% accuracy to predict RA disease status. An independent genomic dataset
from 868 RA patients and 1,194 control subjects of the North American Rheumatoid Arthritis Consortium successfully
validated the results obtained using the Wellcome Trust Case Control Consortium data. In conclusion, this genome-wide
homozygosity association study provides an alternative to allelic association mapping for the identification of recessive
variants responsible for RA. The identified RA-associated ROHs uncover recessive components and missing heritability
associated with RA and other autoimmune diseases.
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Introduction
Rheumatoid arthritis (RA, OMIM #180300), characterized by
damage to the synovial joints, is a chronic inflammatory disorder
with a multifactorial etiology and a polygenic mode of inheritance
[1,2,3,4,5]. RA patients have a shorter life expectancy (by ,3–10
years) and a higher mortality rate (,1.5–1.6 fold) compared with
the general population [6,7]. The worldwide prevalence rates and
sibling-relative risks of RA are ,0.3%–1.2% and 5–10-fold
greater, respectively [8,9]. Despite differences in the genetic
backgrounds of RA patients, the significance of the HLA-DRB1-
shared epitope (6p21.3) [10,11,12,13] and PTPN22 (1p13.3-p13.1)
[14,15,16,17,18,19,20] in the genomes of RA patients has been
well replicated in different genetic studies.
With the availability of high-throughput genotyping techniques,
genome-wide single nucleotide polymorphism (SNP) arrays (e.g.,
Affymetrix GeneChip and Illumina BeadChip technologies) have
been well developed and broadly applied to identify SNPs/genes
associated with complex diseases [21]. Large-scale genome-wide
association studies of RA have been carried out [17,18,20]. These
studies, which have been replicated, identified several new RA-
associated genes, including TRAF1/C5 (9q33-q34) [17,19,22],
TNFAIP3 (6q23) [18,19,23], and CTLA4 (2q33) [18,19,20].
Additional RA-associated genes have been found, which are
pending confirmation, including STAT4 (2q32.2–32.3) [24], CD40
(20q13) [19], REL (2p13-p12) [25], PRKCQ (10p15) [26], and
PADI4 (1p36.13) [16]. Although previous studies have established
allelic associations between RA and certain genomic regions, all of
the genes that contribute to RA have not been found [27], i.e.,
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identified [20]. Genome-wide homozygosity association mapping
provides an alternative to allelic association mapping for
identification of recessive-acting susceptibility genes, uncovering
missing heritability, and understanding the complex etiological
mechanism(s) of RA.
A run of homozygosity (ROH) denotes a contiguous set of
homozygous genotypes in an intact genomic region. A practically
used definition of ROH allows a rich homozygote region
interrupted by a small number heterozygous genotypes arising
from genotyping errors, missing genotypes, or mutations. An
ROH that includes a sizable tract of homozygosity and deviates
from a random distribution in the genome is denoted as
‘‘homozygosity disequilibrium’’ in this study. This type of ROH
may result from various mechanisms including: 1) chromosomal
aberrations, (e.g., uniparental disomy, hemizygous deletion, and/
or loss of heterozygosity [28,29,30,31,32]); 2) autozygosity as a
consequence of inbreeding, consanguineous marriage, or a recent
common ancestor [33,34,35,36,37]; and 3) natural selection, e.g.,
positive selection or selective sweep [38,39,40]. Homozygosity
disequilibrium has frequently been observed in the general
outbred population [34,41,42], but it is also not entirely benign
as it increases the susceptibility to diseases such as neurodevelop-
ment-related disorders [40,43] and other autoimmune diseases
[44].
Homozygosity mapping aims to identify ROH(s) associated with
disease states and was originally developed to map genes
responsible for recessive diseases by using genetic marker data
from inbred pedigrees [45,46,47,48,49]. Recent studies have also
showed that homozygosity association mapping is a statistically
powerful method when identifying susceptibility genes associated
with complex diseases [40,43], cancers [50,51,52,53], and
phenotypic traits [54,55,56]. Various statistical methods of
homozygosity association mapping have been developed in order
to analyze genotype data [35,53,57,58,59] or fluorescence
intensity data [60,61,62,63] from SNP microarrays. To the best
of our knowledge, however, studies have not been performed for
genome-wide homozygosity association mapping for RA. Addi-
tionally, ROHs have not been used as genetic markers for the
prediction of RA status. Instead of focusing on allelic association as
have previous genome-wide association studies for RA [17,18,20],
this study examined the hypothesis that ROHs act as recessive-
acting determinants in the underlying genetic mechanisms of RA
and identified RA-associated ROHs using genome-wide homozy-
gosity association mapping.
Results
Power calculations
Based on the simulation procedures described in Appendix S1,
values for the powers of simulated genome-wide homozygosity
association mappings were calculated using 2,000 patients and
3,000 controls in a simulation study of 1,000 replications (Figure 1).
We always used a genome-wide significance level of 2log10(p).8.
First, we considered the scenario for which a disease-associated
ROH consisted of L consecutive SNPs (L=200). When 30%, 20%,
and 10% of the RA patients carried this ROH (effect size, d,
=0.3, 0.2, 0.1), the power needed to detect the ROH was
calculated as 1.000, 1.000, and 0.814, respectively, for a genome
scan using a window size (W) of 100 SNPs (W=100), or calculated
as 1.000, 1.000, and 0.790, respectively, for W=150, or as 1.000,
1.000, and 0.795, respectively, for W=200. We also incorporated
a heterozygous interference value (e), as a fraction that denoted
incomplete homozygosity in the disease-associated ROH that may
be caused by genotyping errors or unknown mutation mecha-
nisms. The power required for no heterozygous interference was
very similar to the power required for 10% heterozygous
interference. When e=0.2 and d=0.3 or 0.2, the power was
1.000. However, the power was reduced to 0.141 for a genome
scan with W=100, reduced to 0.263 for W=150, and to 0.463 for
W=200 (when e=0.2 and d=0.1). We also considered a disease-
associated ROH for L=150 or 100 and found the powers to be
very similar to that found for L=200.
Genome-wide homozygosity association scans
We conducted genome-wide homozygosity association scans
with W=100, 150, and 200 for the Wellcome Trust Case Control
Consortium (WTCCC) SNP data (WTCCC_100, WTCCC_150,
and WTCCC_200, respectively). Each genomic scan identified
ROHs that satisfied the genome-wide significance criterion of
2log10(p).8 (Figure 2). The identified regions and the respective
maximum values of 2log10(p) within the identified regions are as
follows. The WTCCC_100 scan identified three regions on
chromosome 6p [2log10(p)=8.0769, 2log10(p)=37.5332, and
2log10(p)=9.8852] and one region on 9q [2log10(p)=9.7484].
The WTCCC_150 scan identified two regions on chromosome 6p
[2log10(p)=34.2091 and 2log10(p)=9.0952] and one region on
17p [2log10(p)=8.5038]. The WTCCC_200 scan identified two
neighboring regions on 6p [2log10(p)=22.6591 and
2log10(p)=8.3644]. All three scans identified two overlapping
ROHs located on chromosome 6p.
The first of these overlapping ROHs ranged from
32,451,664 bp to 32,846,093 bp and is located within the human
major histocompatibility complex (MHC) region at 6p21.3, and
the second ranged from 32,933,485 bp to 33,585,118 bp and
overlaps the MHC region (Figure 3). The two regions are located
in different blocks of linkage disequilibrium (LD). The names of
the genes within these two regions are shown in red in Figure 3.
The first region contains 10 genes (from BTNL2 to HLA-DQB2),
and the number of SNPs and the average intermarker distance are
125 and 3.1554 kb, respectively. The maximum 2log10(p) values
for the scans are 37.5332 for WTCCC_100, 34.2091 for
WTCCC_150, and 22.6591 for WTCCC_200. The second
region contains 33 genes (from PSMB9 to ZBTB9), and the
number of SNPs and the average intermarker distance are 134
and 4.8629 kb, respectively.
The proportion that RA patients carried a specific ROH
(pROH) is higher than in normal controls in the two regions of
homozygosity disequilibrium. For sliding windows anchored by
SNPs within the first region, the maximum number of pROHs, as
a fraction, for the patient data is 0.2206 for WTCCC_100, 0.2331
for WTCCC_150, and 0.2071 for WTCCC_200. These values
are greater than those of the controls: 0.0996 for WTCCC_100,
0.1003 for WTCCC_150, and 0.1003 for WTCCC_200. In the
second region, the maximum 2log10(p) values are 9.8852 for
WTCCC_100, 9.0952 for WTCCC_150, and 8.3644 for
WTCCC_200. The maximum number of pROHs is 0.1381 for
WTCCC_100, 0.1331 for WTCCC_150, 0.1341 for
WTCCC_200, and these figures are greater than the maximum
number of pROHs for the normal control data (0.1003 for
WTCCC_100, 0.1003 for WTCCC_150, and 0.1003 for
WTCCC_200).
We investigated the correlation between the presence of these
ROHs and RA disease status for anchoring SNPs within the two
regions that satisfy 2log10(p).8 (Figure 3). The first region
(ROH1) contains 26 anchor SNPs (rs9268831 to rs9273363) and
five genes (HLA-DRB9, HLA-DRB5, HLA-DRB6, HLA-DRB1, and
HLA-DQA1) (Figure S1). The second region (ROH2) contains 34
ROHs Related to Rheumatoid Arthritis in the MHC
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DPA1, HLA-DPB1, RPL32P1, and LOC442203) (Figure S1). A
statistical discriminant analysis of 60 anchor SNPs (rs9268831 to
rs7764491) showed that the highest average accuracy for
predicting RA status is 0.6201 and is associated with SNP16
(rs2027852), which is flanked by HLA-DRB6 and HLA-DRB1. The
ROH anchored at rs2027852 was then used to predict RA status
for the data from 868 RA patients and 1,194 controls of the North
American Rheumatoid Arthritis Consortium (NARAC). The
prediction accuracy is 0.5790.
The genetic heterogeneity of RA patients was investigated next.
The distribution of pROH in RA patients at windows anchored by
the 60 SNPs is shown in Figure S1. The pROH pattern suggests
that there are three SNP groups (rs9268831 to rs7749092,
rs2027852, and rs9270986 to rs9273363) in ROH1, and that
there are two SNP groups (rs10807118 to rs3077 and rs9348904 to
rs7764491) in ROH2. Within each SNP group, the pROH pattern
is very similar. Therefore, only one ‘‘tag’’ anchor SNP was
investigated further. These anchor SNPs are rs9268831 in HLA-
DRB9, rs2027852 flanked by HLA-DRB6 and HLA-DRB1,
Figure 1. Calculated powers for simulated genome-wide homozygosity association scans. The simulated genome-wide homozygosity
association scans included 2,000 patients and 3,000 controls and used 2log10(p).8 for the threshold of statistical significance. Parameters for the
calculations included: The proportion of patients carrying the ROH (d=0.1, 0.2, or 0.3) controlled the effective size of a scan. The number of evenly
spaced SNPs (L=100, 150, or 200 SNPs) determined the length of the true disease-associated ROH. The heterozygous interference was defined as the
fraction of heterozygous-call SNPs in the true disease-associated ROH (e=0, 0.1, or 0.2). W=100, red solid line, circles; W=150, blue dashed line,
triangles; W=200, green dotted line, crosses.
doi:10.1371/journal.pone.0034840.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34840Figure 2. Genome-wide homozygosity association scans. The values of 2log10(p) at the anchor SNPs for the three genome-wide
homozygosity association scans, WTCCC_100, WTCCC_150, and WTCCC_200, are displayed. The purple, horizontal reference lines indicate
2log10(p)=8, the cut-off used to test for significance. Two peaks with 2log10(p).8 in the MHC region on chromosome 6p21.3 were found for all
three scans. The bottom panel shows an expanded plot containing the region of the two peaks. WTCCC_100, blue line, circles; WTCCC_150, green
line, crosses; WTCCC_200, orange line, triangles.
doi:10.1371/journal.pone.0034840.g002
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HLA-DPB1. Thirty-two ROH-carrying categories for the patients
were identified using the presence or absence of ROHs anchored
by the five SNPs. Vectors made of five indicator variables describe
the categories. When the value of the ith indicator was 1, the
genomic segment anchored by the ith anchor SNP carried an
ROH; otherwise, the value of the indicator was 0. Seven of the
categories have a pROH .2% in RA patients; the pROHs are
P(0,0,0,0,0)=60.13%, P(1,0,0,0,0)=7.5%, P(1,1,1,0,0)=6.85%,
P(0,0,0,1,1)=6%, P(0,1,0,0,0)=3.65%, P(0,0,0,0,1)=3.05%, and
P(1,1,0,0,0)=2.65%. Except for the non-carrying category
(0,0,0,0,0), the pROH values in the RA patient group are greater
than those for the control group (i.e., risk category). The finding
that RA patients carry different ROHs partially reflects the genetic
heterogeneity of RA.
Copy number determination
We detected genomic deletions (copy number ,2) and
amplifications (copy number .2) in the MHC regions of the
2,000 RA patients and 3,000 controls from the WTCCC study
(Figure 4). Regarding the genomic deletions, no region in the RA
patients was found to have a significantly greater proportion (a
proportion difference .2%) of deletions than regions of the
controls. Conversely, one region from the controls, rs1431403
(33,155,009 bp) to rs7764491 (33,168,818 bp), had a greater
proportion of deletions than the regions from RA patients. The
Figure 3. Genes and LD structures in the MHC region identified by the homozygosity association scans. The genes and intermarker LDs
in the regions containing ROHs are displayed. The two dotted, red vertical lines demarcate the MHC region from 29,732,804 bp to 33,268,223 bp on
chromosome 6p. The regions identified by the WTCCC_100, WTCCC_150, and WTCCC_200 scans are identified by the sky blue, light green, and
orange horizontal bars, respectively. The outermost vertical bars denote the first SNP (gray tick) in the first window and the last SNP (gray tick) in the
last window. Additionally, the first anchor SNP and the last anchor SNP for regions with 2log10(p).8 are marked using bold ticks. If two regions
identified by the same genome scan overlap, the segment containing the overlapping regions is shown in dark blue, green, and orange for
WTCCC_100, WTCCC_150, and WTCCC_200, respectively. The names of genes within the annotated regions are given above the bars. The names of
genes in the regions identified by the three scans are shown in red, and the names of the genes identified by one or two scans are shown in blue. The
location and width of the bars that prefix the gene names reflect the physical position and the size of the genes. LD structures are provided in the
lower panels in which the higher intermarker LDs are in red.
doi:10.1371/journal.pone.0034840.g003
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amplifications, three regions from the RA patients had a greater
proportion of amplifications (a proportion difference .2%) than
those of the controls. The three regions are rs2516670
(30,542,978 bp) to rs9295931 (30,977,693 bp), rs9295961
(31,275,477 bp) to rs9295967 (31,291,999 bp), and rs2736177
(31,694,073) to rs2299851 (31,826,581 bp), and the average
proportion differences for the RA patient data minus the control
data are 0.0282, 0.0201, and 0.0214, respectively.
Discussion
Our study represents the first genome-wide homozygosity
association scans for RA; we pinpointed important RA-associated
ROHs in the MHC region and confirmed this region to be
associated with RA [64,65]. For the two ROHs, the window with
the best prediction accuracy 62% is anchored by the SNP
rs2027852. We validated the results derived from the WTCCC
data by using the independently acquired NARAC data (Figure
S2). Homozygosity disequilibrium was consistently found in the
MHC region, for which the respective maximum values of
2log10(p) for NARAC_100 (W=100) and NARAC_200
(W=200) are 2log10(p)=7.6973 and 2log10(p)=7.1334, respec-
tively, which are highly significant values.
The SNP rs2027852 is flanked by HLA-DRB6 and HLA-DRB1.
The HLA-DRB1-shared epitope is an important determinant of
RA susceptibility [10]. Associations between HLA-DRB1 and RA
susceptibility [10,11,12,13,66,67] and between HLA-DRB1 and
the severity of RA [68,69] have been made. In addition to HLA-
DRB1, a second relevant ROH includes HLA-DPA1 and HLA-
DPB1. Previous studies produced inconclusive results concerning
the relationship between RA and HLA-DPA1 and HLA-DPB1
[70,71,72]. Despite the evidence of statistical significance support-
ed by this study, more functional studies are necessary to re-
confirm the genetic associations with RA.
We found that the observed homozygosity disequilibrium in the
MHC region is not explained by mechanisms associated with
hemizygous deletion because our copy number analysis found only
a very small proportion of the samples had acquired DNA
deletions in the MHC region (Figure 4). The RA-related ROHs
probably were not generated from copy-neutral chromosomal
aberrations, e.g., uniparental disomy and loss of heterozygosity,
because such chromosomal abnormalities often result in severe
inherited disorders and cancers, which the patients of the study did
not have. Inbreeding, as the cause of the homozygosity
disequilibrium, also seems unlikely as the patients were not an
inbred population(s).
Selective sweep, a type of natural selection, seems to be a
plausible mechanism for the appearance of homozygosity
disequilibrium in general population [40]. Homozygosity disequi-
librium in the MHC region, which has been shown to contain the
important functional genes related to RA and other autoimmune
diseases [64,65,73,74], results in a loss of genetic diversities and
thereby influences quantitative and/or qualitative alternations of
expression profiles. Some studies have found that autoimmunity
susceptibility genes are positively selected in RA [75,76,77,78].
Selected alleles accumulate in the gene pool over time and
Figure 4. Gene amplifications and deletions in the MHC region. The fraction and numbers of RA patients and controls who carried
amplifications and deletions in the MHC region are showed. The top and bottom panels show the results for the amplifications and deletions,
respectively. In both panels, the results for the RA patients and controls are indicated as red dots and blue crosses, respectively. The fraction of RA
patients and controls is shown on the left y axis, and the number of RA patients and controls is shown on the right y axis.
doi:10.1371/journal.pone.0034840.g004
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Genomic regions with a small recombination fraction and a large
LD tend to contain even more ROHs than do regions with large
recombination fractions or a small LD; for example, the time
necessary for a region to be affected by selective pressure is so short
that a limited number of recombinations prevents a rapid decay of
LD and thereby promotes the occurrence of ROHs [39]. For type-
1 diabetes, a relevant study has also pointed out significant SNP
identity and conserved extended haplotypes in the MHC region
[44]. That and our study reinforce the idea that natural selection
may be critical to maintaining functionally important genes [79]
and susceptibility to complex diseases [80].
Our study attempted to tackle several difficulties associated with
homozygosity association mapping, which is defined as the
identification of ROHs associated with a given disease. However,
the observed, extended homozygosity may contain a run of
homozygotes, hemizygotes, or a combination of both, and the
different types of runs may reflect different genetic mechanisms
associated with a disease. For genotype-based homozygosity
association mapping, it is difficult to distinguish the differences
between true homozygosity (a homozygous run) and spurious
homozygosity (a hemizygous run) [81,82]. Therefore, we em-
ployed genotype-based homozygosity association scans and
intensity-based copy-number characterization to discriminate
between copy-neutral homozygosity and deletion-induced hemi-
zygosity for the RA-associated ROHs. Additionally, missing
genotypes or heterozygous calls that arise from genotyping errors
or recent mutations may interrupt a homozygous run (imperfect
ROH). The genome-wide homozygosity association mapping used
in this study overcame these obstacles by imputing missing
genotypes and correcting for the modest heterozygous interference
with the use of a local polynomial fit [53].
The required minimum power value and sample size for
genome-wide homozygosity association mapping for complex
diseases have not been explicitly determined in previous studies
[81]. Our simulations provided an objective assessment of how the
values for the power and the number of samples affect the results,
and the results for the simulations suggest that we used sufficient
sample numbers to attain reasonable statistical power to detect
RA-associated ROHs in this study. In contrast to a single-SNP
recessive model, the homozygosity association tests provided by
LOHAS and ROH programs are multilocus analysis methods.
The two multilocus methods make use of genetic information from
extent of homozygosity, which is a function of LD, recombination
fraction, and population history [40]. Recessive-acting disease
alleles in an ROH predisposing to a disease are accumulated and
made use to elevate the low power of a single-SNP analysis due to
rare disease alleles at single SNPs.
Population substructure/admixture is an important confound-
ing factor in genome-wide case-control association studies.
Ignoring the difference of genetic substructure/admixture in case
and control groups may lead to false-positive findings. We thus
also performed genome-wide homozygosity association test with
an adjustment for population substructure/admixture using
principal components. We regressed the homozygosity intensity
estimates from LOHAS software [53] on case/control disease
status and the first 10 principal components from EIGENSTRAT
software [83] to validate genetic association we identified in the
MHC region. We found that genetic association between the
identified ROHs in the MHC region and RA disease status
remained very significant after taking population substructure/
admixture into account (Figure S3). The maximum 2log10(p)
values for the scans were 28.4155 for WTCCC_100, 23.1904 for
WTCCC_150, and 14.6061 for WTCCC_200 in the first peak
region and 8.6160 for WTCCC_100, 7.5250 for WTCCC_150,
and 7.4240 for WTCCC_200 in the second peak region. The
results explain that our findings in the MHC region are valid and
robust to population substructure/admixture.
RA-associated ROHs identified by LOHAS software was also
evaluated by a second homozygosity association method. ROH
program [40], which has been integrated into HelixTree software
(HelixTree, Inc.), was run to examine homozygosity association in
the MHC region. Several parameter combinations for defining an
ROH were considered in the analysis using ROH program. At the
Bonferroni significance level, two significant RA-associated ROHs
identified by LOHAS software were validated by ROH program
(Figure S4).
In conclusion, our genome-wide homozygosity association study
used high-density SNP array data to provide an alternative
method to an allelic association study for mapping RA-
susceptibility genes. Excess ROHs were found in the MHC
regions of RA patients compared with those of controls, which
uncovered a recessive component and missing heritability for RA
and possibly other autoimmune diseases.
Materials and Methods
Study materials
We used SNP data from the WTCCC [18] that was obtained
from 1,999 RA patients and 3,002 controls. Of the control
samples, 1,502 were from the 1958 British Birth Cohort study and
1,500 were from the UK Blood Service. All samples were
genotyped using the Affymetrix 500K SNP GeneChip system
(Affymetrix Inc., Santa Clara, CA, USA). Genotypes were called
using the genotype-calling algorithm, CHIAMO [18]. Samples
from 868 RA patients and 1,194 normal controls participating in
the NARAC [17] were used to independently validate the results
of the WTCCC data. All samples were genotyped using the
Infinium HumanHap550 SNP BeadChip system (Illumina Inc.,
San Diego, CA, USA). Genotypes were called with the genotyping
module of BeadStudio. All samples passed a quality control
examination. The SNP and gene annotation information includ-
ing the physical positions and the associated genes were taken from
the NCBI dbSNP Build 123.
Statistical methods
A genome-wide non-parametric association test was applied to
map regions of homozygosity disequilibrium in the genomes of the
RA patients. Given a target SNP (anchor) on a chromosome, a
window containing the target SNP and W-1 nearest neighbor
SNPs was constructed. Windows were slid along the chromo-
somes. For the genomes of each individual studied and for each
window, a homozygote intensity (fraction) of SNPs was estimated
by non-parametric local polynomial fitting [84] with a tricubic
weight function. Dependent variable in the local regression is the
homozygous/heterozygous states of SNPs and independent
variable is physical position of the SNPs [53]. Then, in each
window, the estimated homozygote intensities for each individual
were compared with the median homozygote intensities for all
patient and control samples to calculate the Kullback-Leibler
distance [85]. The larger the distance was, the greater the fraction
of homozygous SNPs. A Wilcoxon rank sum test [86] was applied
to compare the Kullback-Leibler distances for the patient and
control groups, and then to identify windows/regions of greater
median homozygote intensity for the patient genomes. The
aforementioned procedures were executed by using LOHAS
software (http://www.stat.sinica.edu.tw/hsinchou/genetics/loh/
LOHAS.htm) [53]. Homozygote intensities in the regions of
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analysis [87] and a 10-fold cross-validation procedure. The
average prediction accuracy of the fitted classifiers for the RA
patients and the controls was calculated using the R package.
Copy number analysis was performed using the Partek Genomics
Suite (Partek, Inc.). Copy numbers were determined from the
allele intensities with an adjustment for local GC content. Copy
number alternations, including gene amplifications and deletions,
were inferred by genomic segmentation for which the default
parameters recommended by Partek were used.
Supporting Information
Figure S1 Distribution of the fraction of RA patients
carrying ROHs in the two regions of homozygosity
disequilibrium. There are 60 anchor SNPs in the two regions
that satisfy 2log10(p).8. The first region (ROH1) contains 26
anchor SNPs and 5 genes, and the second region (ROH2) contains
34 anchor SNPs and 4 genes. A red point is plotted if a patient
carried an ROH at an anchor SNP; otherwise the space is blank.
The relative positions of 9 genes in these 2 regions are shown, and
the 5 anchor SNPs used to tag rs9268831, rs2027852, rs9272723,
rs3077, and rs9277542 are also marked.
(PPT)
Figure S2 Genome-wide homozygosity association
scans for the NARAC and WTCCC data. The values of
2log10(p) at anchor SNPs for the two genome-wide homozygosity
association scans, NARAC_100 (W=100) and NARAC_200
(W=200), are displayed. A genome-wide significance level of
2log10(p)=8 is marked by the purple, horizontal line. The results
for the WTCCC_100 and WTCCC_200 scans are provided for
comparison. Peaks with 2log10(p) values above the significance
line and signals that were consistently identified by the four scans
were found in the MHC region on chromosome 6p21.3.
(TIF)
Figure S3 Homozygosity association scans with an
adjustment for population substructure/admixture in
the MHC region for the WTCCC data using principal
components. The values of 2log10(p) at the anchor SNPs for the
three homozygosity association scans, WTCCC_100,
WTCCC_150, and WTCCC_200, are displayed. WTCCC_100,
blue line, circles; WTCCC_150, green line, crosses;
WTCCC_200, orange line, triangles.
(TIFF)
Figure S4 Homozygosity association scans in the MHC
region for the WTCCC data using ROH program. Two
parameters for defining an ROH are required in ROH program:
the minimum run length (Rmin) and the minimum number of
samples (Smin). ROHs are disregarded if the number of
homozygous SNPs is less than Rmin. SNPs are removed if the
number of samples for which that SNP is a member of an ROH is
less than Smin (the details can refer to the user guide of ROH
program in HelixTree software). This analysis considered
Rmin={50, 100, 150, 200} and Smin={100, 150, 200, 250,
300}. Moreover, 10,000 permutations were performed to evaluate
genetic association between affection status of RA and ROHs in
the MHC region. In each subfigure, the horizontal axis denotes
physical position (unit: Mb) on chromosome 6 and the vertical axis
denotes p-value (2log10 scale) from the homozygosity association
test used in ROH program. A green solid line indicates a raw
empirical p-value of homozygosity association tests from 10,000
permutations. Value of the raw empirical p-value is shown above
the green line. Physical positions of starting and ending SNPs of an
ROH are listed below the green line. A red dashed line indicates
the Bonferroni significance level, i.e., 0.05/30 in this analysis. If no
ROH was found under a certain parameter combination of Rmin
and Smin, an empty subfigure is shown.
(TIFF)
Appendix S1 Simulation studies for evaluating power of
the homozygosity association test used in this paper.
(DOC)
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